Similar articles

• Editorial comment on: histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity.

  Haferkamp A. Haferkamp A. Eur Urol. 2008 Jun;53(6):1253. doi: 10.1016/j.eururo.2008.02.038. Epub 2008 Mar 7. Eur Urol. 2008. PMID: 18343561 No abstract available.
• Editorial comment on: Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results.

  Fowler CJ. Fowler CJ. Eur Urol. 2009 Mar;55(3):712. doi: 10.1016/j.eururo.2008.08.050. Epub 2008 Sep 2. Eur Urol. 2009. PMID: 18814958 No abstract available.
• Editorial comment on: Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results.

  Schurch B. Schurch B. Eur Urol. 2009 Mar;55(3):711-2. doi: 10.1016/j.eururo.2008.08.049. Epub 2008 Sep 2. Eur Urol. 2009. PMID: 18814956 No abstract available.
• The case for bladder botulinum toxin application.

  Kim DK, Thomas CA, Smith C, Chancellor MB. Kim DK, et al. Urol Clin North Am. 2006 Nov;33(4):503-10, ix. doi: 10.1016/j.ucl.2006.06.010. Urol Clin North Am. 2006. PMID: 17011386 Review.
• Botulinum toxin for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia.

  Antunes AA, Srougi M, Coelho RF, de Campos Freire G. Antunes AA, et al. Nat Clin Pract Urol. 2007 Mar;4(3):155-60. doi: 10.1038/ncpuro0735. Nat Clin Pract Urol. 2007. PMID: 17347660 Review.